Clearline Capital’s Avita Medical RCEL Stock Holding History

Clearline Capital’s Portfolio RCEL Stock Details RCEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-20,662	Closed	-$164K	–	164
2024 Q2	$164K	Hold	20,662	–	–	﹤0.01%	140
2024 Q1	$331K	Hold	20,662	–	–	0.02%	115
2023 Q4	$283K	Hold	20,662	–	–	0.02%	95
2023 Q3	$302K	Sell	20,662 -29,681	-59%	-$502K	0.03%	119
2023 Q2	$856K	Hold	50,343	–	–	0.05%	91
2023 Q1	$703K	Hold	50,343	–	–	0.11%	84
2022 Q4	$332K	Hold	50,343	–	–	0.06%	107
2022 Q3	$265K	Hold	50,343	–	–	0.03%	128
2022 Q2	$239K	Hold	50,343	–	–	0.03%	120
2022 Q1	$427K	Hold	50,343	–	–	0.05%	111
2021 Q4	$603K	Hold	50,343	–	–	0.07%	107
2021 Q3	$892K	Hold	50,343	–	–	0.08%	106
2021 Q2	$1.03M	Buy	50,343 +10,937	+28%	+$216K	0.15%	90
2021 Q1	$781K	Sell	39,406 -51,300	-57%	-$1.19M	0.1%	80
2020 Q4	$1.69M	Buy	+90,706	New	+$1.99M	0.38%	59

Other funds holding RCEL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EIM

Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Clearline Capital's RCEL Position: Q3 2024 in Review

Clearline Capital sold out of Avita Medical (RCEL) in Q3 2024, closing a stake of 20,662 shares — an estimated $164K sold.

Clearline Capital first reported a position in RCEL in Q4 2020 and held it in 15 quarters. The position peaked at $1.69M in Q4 2020. 67 funds tracked by Wall St. Rank hold RCEL as of Q3 2024.

Clearline Capital reported no remaining Avita Medical position as of Q3 2024 after selling out during the quarter.
Clearline Capital sold 20,662 Avita Medical shares in Q3 2024, an estimated $164K.
Clearline Capital first reported a position in Avita Medical in Q4 2020 and held it in 15 quarters.
Clearline Capital's Avita Medical position peaked at $1.69M in Q4 2020.
67 funds tracked by Wall St. Rank held Avita Medical as of Q3 2024.

Based on Clearline Capital's 13F filing for Q3 2024, filed 14 Nov 2024.